Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
7,125
datasets available to search
ShareScore release 0.9.0
Dataset results
7,125 results for “Prostate cancer;”
Grainyhead-like 2 is essential for androgen receptor expression and activity in prostate cancer (ChIP-seq)
GEO Series GSE80256. Homo sapiens. 4 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Expression data from prostate cancer and osteoblast co-cultures
GEO Series GSE73044. Rattus norvegicus; Homo sapiens. 9 samples. Type: Expression profiling by array.
Effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells
GEO Series GSE17167. Homo sapiens. 6 samples. Type: Expression profiling by array.
H3K4me3 Marks in Normal and Cancerous Prostate Cells
GEO Series GSE38682. Homo sapiens. 2 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Expression data in JDCaP prostate cancer xenograft model before and after expression of AR splice variants
GEO Series GSE90922. Homo sapiens. 9 samples. Type: Expression profiling by array.
CDK4/6 inhibition enhances the tumor-suppressive activity of high-dose androgens in castration-resistant prostate cancer [ChIP-seq]
GEO Series GSE179684. Homo sapiens. 25 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
CSN5 inhibition in prostate cancer cells
GEO Series GSE173469. Homo sapiens. 38 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence [Cell line ChIP-Seq]
GEO Series GSE197774. Homo sapiens. 22 samples. Type: Expression profiling by high throughput sequencing.
CHD1 and H3K4me3 ChIP-seq in prostate cancer cell line PC-3
GEO Series GSE91401. Homo sapiens. 12 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
EZH2 alters aggressive variant prostate cancer subtype evolution, but is not required for neuroendocrine prostate cancer. [scRNA-seq]
GEO Series GSE296986. Mus musculus. 17 samples. Type: Expression profiling by high throughput sequencing.
16 prostatic cancer cell lines and sensitivity to an anticancer tumor agent dasatinib
GEO Series GSE9633. Homo sapiens. 16 samples. Type: Expression profiling by array.
SIX2 promotes cell plasticity via Wnt/beta-catenin signalling in androgen receptor independent prostate cancer (ChIP-seq)
GEO Series GSE235956. Homo sapiens. 3 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Multi-cohort effectiveness of Gallium-68-PSMA PET/CT and pelvic 3Tesla multi-parametric magnetic resonance imaging in the diagnostic and therapeutic work-up of prostate cancer (MoH RF-2016-02364230)
<p>The project "<strong>Multi-cohort effectiveness of Gallium-68-PSMA PET/CT and pelvic 3Tesla multi-parametric magnetic resonance imaging in the diagnostic and therapeutic work-up of prostate cancer</strong>" is funded by Italian Ministry of Health (project code: <strong>RF-2016-02364230</strong>)</p><p> </p><p>Based on preliminary data, the project hypothesis was that diagnostic accuracy of 68Ga-PSMA PET/CT is comparable to that of mp-3TMRI in pts with pCa. If that is the case, the use of 68Ga-PSMA PET/CT will lead to shorter waiting lists, faster scanning time and lower costs compared to mp-3TMRI. The 1st goal of this project is to guide or replace invasive procedures with a non invasive approach such as mp-3TMRI or 68Ga-PSMA PET/CT. The secondary aim is a comparative analysis of the 2 techniques. </p><p><strong>Specific Aim 1:</strong></p><p>Characterize the incremental benefit of pelvic mp-MRI and 68Ga-PSMA PET/CT in: guiding TRUS-B, to identify clinicallysignificant PCa in pts who are negative at first-round TRUS-B and/or are undergoing AS.</p><p>Stage accuracy of pelvic mp-MRI and 68Ga PSMA PET/CT during the pre-surgical work-up of high-risk PCa pts and PCa pts who are candidates for nerve-sparing surgery.</p><p>The secondary aim is a comparative analysis of the 2 techniques.</p><p><strong>Specific Aim 2:</strong></p><p>Evaluate the accurancy of 68Ga-PSMA PET/CT (i.e. Sensitivity, SE; specificity, SP) in detecting sites of biochemical PCa recurrence compared to routinely-used diagnostic tools (TRUS-B, bone scan, diagnostic CT, MRI and 18F-FCH PET/CT).</p><p>The secondary objectives are SE for different PSA values and SE for different Gleason score.</p><p><strong>Specific Aim 3:</strong></p><p>Evaluate the efficacy in terms of Disease Control Rate (DCR) and the safety of 2 different administration schedules of 177Lu-PSMA in a cohort (C) of metastatic CRPC pts previously treated with standard therapy.</p>
Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer
ClinicalTrials.gov study NCT04377152. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Stockholm3 Use Prior to MRI for Prostate Cancer Detection in a Clinical Care Pathway: a Multi-centered Validation
ClinicalTrials.gov study NCT06573736. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer
ClinicalTrials.gov study NCT00244920. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Apatinib in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment for Symptomatic Metastatic Prostate Cancer
ClinicalTrials.gov study NCT02998242. IPD Sharing: YES. Countries: 0. Publications: 0.
Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
ClinicalTrials.gov study NCT03147196. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Selenium in Preventing Prostate Cancer
ClinicalTrials.gov study NCT00978718. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer
ClinicalTrials.gov study NCT06527690. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.